摘要
癌症是与细胞生长异常有关的疾病。癌细胞生长不可控并能入侵和扩散到身体的其他部位。 本病为世界主要死因之一,已成为科学研究的重要课题。另一方面,过渡金属在不同的生活系统中起着基础性的作用。特别是,金属药物是新的具有不同治疗作用的强大工具。到目前为止,各种金属药物在化疗方面具有很强的生物活性。在这一领域,顺铂是第一个具有高度相关性的癌症治疗的无机化合物。该化合物是临床使用的主导药物。毒性和耐药性问题促使了其他具有更好的临床前景的铂类药物的发展,同时引起了科学家对V,Ru和 Cu化合物抗肿瘤特性的研究兴趣。研究表明,这些金属的配合物是新的金属是可用于治疗多种癌症如肺癌,结肠癌,乳腺癌,膀胱等的基础药物。 本文概括了铜,钌和钒对多种有机和无机化合物以及抗肿瘤新进展的影响,这些金属衍生化合物针对与癌症相关的细胞信号通路中的DNA或细胞蛋白。本文还对这些金属药物引起细胞死亡的机制也进行了讨论。 这些细胞凋亡的机制和化学结构与生物活性之间的关系对于设计新的具有广阔的应用前景的金属药物至关重要。
关键词: 抗癌药物,细胞培养,铜,作用机理,钌,钒。
Current Medicinal Chemistry
Title:Vanadium, Ruthenium and Copper Compounds: A New Class of Nonplatinum Metallodrugs with Anticancer Activity
Volume: 24 Issue: 2
Author(s): Ignacio Esteban Leon, Juan Fernando Cadavid-Vargas, Ana Laura Di Virgilio, Susana Beatriz Etcheverry.
Affiliation:
关键词: 抗癌药物,细胞培养,铜,作用机理,钌,钒。
摘要: Cancer is a group of diseases involving abnormal cell growth. The cells grow uncontrollably with the potential to invade and spread to other parts of the body.
This disease is one of the principal death causes in the world, thus becoming a significant topic of scientific research. On the other hand, transition metals play a fundamental role in different living systems. In particular, Metallodrugs represent new and powerful tools for diverse therapeutic applications. To date, various metallodrugs display interesting biological activities for chemotherapy. In this field, cisplatin was the first inorganic compound with high relevance in cancer treatment. This compound was a leader agent in clinical use. Toxicity and resistance problems trigger the development of other platinum drugs with better clinical perspective and also raise the scientific interest for the putative antitumor properties of V, Ru and Cu compounds. Several scientific articles show that complexes of these metals are the new metal-based drugs used in the treatment of several cancers, such us, lung, colon, breast, bladder, etc.
In this review we recapitulate current information and new advances on antitumor in vitro effects of several organic and inorganic compounds derived from copper, ruthenium and vanadium. These metal derived compounds targeting DNA or cell proteins involved in cell signaling pathways related to cancer. The mechanisms of cell death of these metallodrugs have also been comprehensibly reviewed.
The knowledge of these mechanisms of death and the relationship between chemical structure and biological activity may be useful for the design of new metal-based drugs with promising pharmacologic applications as anticancer agents.
Export Options
About this article
Cite this article as:
Ignacio Esteban Leon, Juan Fernando Cadavid-Vargas, Ana Laura Di Virgilio, Susana Beatriz Etcheverry. , Vanadium, Ruthenium and Copper Compounds: A New Class of Nonplatinum Metallodrugs with Anticancer Activity, Current Medicinal Chemistry 2017; 24 (2) . https://dx.doi.org/10.2174/0929867323666160824162546
DOI https://dx.doi.org/10.2174/0929867323666160824162546 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Pros and Cons of Medical Cannabis use by People with Chronic Brain Disorders
Current Neuropharmacology High Performance Liquid Chromatographic Approaches to Mass Spectrometry Based Metabolomics
Current Metabolomics Impact of Metformin on Male Reproduction
Current Pharmaceutical Design Statins and Cancer
Anti-Cancer Agents in Medicinal Chemistry The Role of ING Tumor Suppressors in UV Stress Response and Melanoma Progression
Current Drug Targets Cancer Chemoprevention with Green Tea Catechins: From Bench to Bed
Current Drug Targets Downstream Carcinogenesis Signaling Pathways by Green Tea Polyphenols: A Translational Perspective of Chemoprevention and Treatment for Cancers
Current Drug Metabolism Thermosensitive Polymeric Hydrogels As Drug Delivery Systems
Current Medicinal Chemistry Chromatin Remodeling Agents for Cancer Therapy
Reviews on Recent Clinical Trials Perspectives Offered by Single-Domain Antibodies in Clinical Diagnostic of Pediatric Tumors
Current Medicinal Chemistry Targeting Angiogenesis in Renal Cell Carcinoma
Current Cancer Drug Targets Pharmacogenetics Strategies: From Candidate Genes to Whole-Genome Association Analysis. Exploratory or Confirmatory Studies?
Current Pharmacogenomics and Personalized Medicine Targeting of Peptide Cytotoxins to LHRH Receptors For Treatment of Cancer
Current Drug Targets Peptide-Receptor Ligands and Multivalent Approach
Anti-Cancer Agents in Medicinal Chemistry The Application of the RNA Interference Technologies for KRAS: Current Status, Future Perspective and Associated Challenges
Current Topics in Medicinal Chemistry A Link Between Chemical Structure and Biological Activity in Triterpenoids
Recent Patents on Anti-Cancer Drug Discovery Hypericin - The Facts About a Controversial Agent
Current Pharmaceutical Design Association of Metronidazole with Cancer: A Potential Risk Factor or Inconsistent Deductions?
Current Drug Metabolism Irradiation Toxicity and Inflammatory Bowel Diseases (IBD): Review
Reviews on Recent Clinical Trials KRAB-Zinc Finger Proteins: A Repressor Family Displaying Multiple Biological Functions
Current Genomics